TMT1B and glioma: To further determine the effect of high METTL7B expression on immunotherapy of glioma patients, ImmuCellAI (http://bioinfo.life.hust.edu.cn/ImmuCellAI#!/), was used to predict immune checkpoint blockade (ICB) therapy response.